Arvinas Holding Company (ARVN)
NASDAQ:ARVN
Want to see ARVN full AI Analyst Report?
ARVN Stock Chart & Stats
$11.00
$0.30(1.54%)
At close: 4:00 PM EST
$11.00
$0.30(1.54%)
Day’s Range― - ―
52-Week Range$6.06 - $14.51
Previous CloseN/A
Volume216.17K
Average Volume (3M)945.77K
Market Cap
$489.07M
Enterprise Value$400.05M
Total Cash (Recent Filing)$614.90M
Total Debt (Recent Filing)$8.60M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Jul 30, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.26
Shares Outstanding64,521,194
10 Day Avg. Volume816,154
30 Day Avg. Volume945,766
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue4.47
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$14.69Price Target Upside33.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$122.96M
Bulls Say, Bears Say
Bulls Say
Platform Validation Via First PROTAC ApprovalVEPPANU's FDA approval provides durable validation of Arvinas' PROTAC modality, materially de‑risking its core technology. That regulatory proof point strengthens partner interest, licensing optionality and long-term platform credibility, improving prospects for sustained collaborations and commercial deals.
Strong Liquidity And Low LeverageA multi-year cash runway and minimal debt give Arvinas durable financial flexibility to fund clinical programs, pursue selective partnerships, and withstand development setbacks without immediate financing. Low leverage preserves negotiating power and reduces near‑term solvency risk for ongoing R&D.
Broad Pipeline And Translational Track RecordA diversified set of discovery-to-clinic programs and demonstrated biomarker/clinical activity create multiple long‑term value pathways. Platform breadth and prior translational success increase the odds that at least one program reaches late‑stage value inflection, reducing single‑asset dependency.
Bears Say
Persistent Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow means Arvinas cannot self‑fund long-term growth without milestone receipts or financing. This structural burn raises dilution and refinancing risk, forces reliance on partner payments and milestones, and constrains capital allocation for simultaneous programs.
Revenue Concentration And Sharp DeclineRevenue is highly dependent on timing and accounting of collaboration receipts, producing volatile top‑line performance. Such concentration reduces predictability of funding, complicates internal planning and makes runway and program financing contingent on milestone realization rather than recurring product cash flow.
Clinical/regulatory And Competitive Execution RiskAn FDA clinical hold and noted safety/competition uncertainty in the KRAS space create persistent execution risk. Regulatory delays raise development costs and timeline uncertainty, while intense KRAS competition and safety signals could limit market opportunity or require further differentiation and trials.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $6.05 and its highest was $14.51 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $489.07M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Jul 30, 2026 which is in 43 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on May 12, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$0.924 by $0.024.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.37.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 64,521,194 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of -$0.9 in its last earnings report, beating expectations of -$0.924. Following the earnings report the stock price went down -0.932%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.69 (33.57% Upside)
$14.69 (33.57% Upside)
Hedge Fund Trend
Decreased
By 174.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $523.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.35%
12-Months-Change
Fundamentals
Return on Equity
-44.39%
Trailing 12-Months
Asset Growth
-35.32%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
ARVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented several major positive developments — notably the landmark FDA approval of VEPPANU (first heterobifunctional PROTAC approval), a global out-license to Rigel, robust early clinical and compelling preclinical data across multiple programs (ARV-102, ARV-806, ARV-393, ARV-6723, pan-KRAS), a healthy cash runway into H2 2028, and significant non-GAAP expense reductions improving financial flexibility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by collaborative accounting changes), a quarter-over-quarter cash decline, an FDA-requested hold on the U.S. ARV-102 Phase 1b pending chronic NHP tox data (delaying U.S. patient dosing), and competitive/safety uncertainties in the KRAS landscape. Overall, the highlights — including the validation of the platform, key partnerships, and multiple programs advancing — materially outweigh the lowlights, supporting a positive outlook for the company.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$14.69
▲(33.57% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.63% Insiders
18.88% Mutual Funds
25.07% Other Institutional Investors
39.66% Public Companies and
Individual Investors